fluacrypyrim and Lung-Neoplasms

fluacrypyrim has been researched along with Lung-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for fluacrypyrim and Lung-Neoplasms

Article	Year
Synthesis of novel strobilurin-pyrimidine derivatives and their antiproliferative activity against human cancer cell lines. Bioorganic & medicinal chemistry letters, 2013, Jun-15, Volume: 23, Issue:12 A series of new strobilurin-pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds I and II. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (8f, IC50=2.2 nM and 11d, IC50=3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds I and II and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin-pyrimidine analogs as potential antitumor agents for the treatment of leukemia. Topics: Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Fatty Acids, Unsaturated; HL-60 Cells; Humans; Leukemia; Lung Neoplasms; Methacrylates; Pyrimidines; Structure-Activity Relationship	2013

Article

Year

Synthesis of novel strobilurin-pyrimidine derivatives and their antiproliferative activity against human cancer cell lines.

Bioorganic & medicinal chemistry letters, 2013, Jun-15, Volume: 23, Issue:12

A series of new strobilurin-pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds I and II. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (8f, IC50=2.2 nM and 11d, IC50=3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds I and II and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin-pyrimidine analogs as potential antitumor agents for the treatment of leukemia.

Topics: Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Fatty Acids, Unsaturated; HL-60 Cells; Humans; Leukemia; Lung Neoplasms; Methacrylates; Pyrimidines; Structure-Activity Relationship

2013